CCO Independent Conference Coverage
2008 Conference on Retroviruses and Opportunistic Infections*
February 3-6, 2008 | Boston, Massachusetts
*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.
Clinical Update on First-Line Antiretroviral Therapy
|
Track 1 of 5
|
|
|
|
   |
- Joel E. Gallant, MD, MPH
- Charles B. Hicks, MD
- Kathleen E. Squires, MD
|
|
|
Management of Treatment-Experienced Patients
|
Track 2 of 5
|
|
|
|
   |
- Joseph J. Eron, Jr., MD
- W. David Hardy, MD
- Kimberly Y. Smith, MD, MPH
|
|
|
Antiretroviral Drug Resistance
|
Track 3 of 5
|
|
|
|
   |
- Eric S. Daar, MD
- Daniel R. Kuritzkes, MD
- Andrew R. Zolopa, MD
|
|
|
Metabolic Complications and Adverse Events
|
Track 4 of 5
|
|
|
|
   |
- Andrew Carr, MD
- Judith S. Currier, MD, MSc
- William G. Powderly, MD
|
|
|
Hepatitis and Opportunistic Coinfections
|
Track 5 of 5
|
|
|
|
   |
- Richard E. Chaisson, MD
- Bruce Polsky, MD
- Jürgen K. Rockstroh, MD
|
|
|
CCO Slideset
HIV/AIDS Update From Boston
 |
|
Comprehensive slideset of the most clinically relevant data from the 2008 Conference on Retroviruses and Opportunistic Infections held in Boston, Massachusetts.
Format: Microsoft PowerPoint (.ppt) | File size: 1,463 KB
|
Expert Highlights
|
Judith S. Currier, MD, MSc, reviews highlights of reports on initial therapy, complications of antiretroviral therapy, and other key topics from the 2008 Conference on Retroviruses and Opportunistic Infections. (5 minutes)
|
 |
Download Audio |
|
Joseph J. Eron, Jr., MD, comments on how the “new kids on the block”—maraviroc, raltegravir, and etravirine—have “grown up” with 48-week data being reported at this meeting. (4 minutes)
|
|
Download Audio |
|
Joel E. Gallant, MD, MPH, reviews highlights of reports on first-line therapies from the 2008 Conference on Retroviruses and Opportunistic Infections. (8 minutes)
|
|
Download Audio |
|
Bruce Polsky, MD, discusses the results of an important ACTG study evaluating whether patients who present with an acute opportunistic infection should start antiretroviral therapy immediately or after treatment for the OI. (7 minutes)
|
|
Download Audio |
|
Andrew R. Zolopa, MD, discusses data from the STEP trial, which demonstrated that the Ad5 trivalent AIDS vaccine failed to reduce HIV-1 acquisition and may increase the risk of acquisition in an Ad5-immune subgroup of vaccine recipients. (5 minutes)
|
|
Download Audio |
Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Contact Info
Educational grants provided by:
Educational grants support only the CME-certified components of this program.
|